Stratec Se

Stratec Se Debt

The Debt of Stratec Se (SBS.DE) as of Oct 29, 2026 is 123.24 M EUR. In the previous year, Debt was 130.53 M EUR — a change of -5.59% (lower).

Debt

123.24 MEUR

YoY

-5.59%

Last updated:

In 2025, Stratec Se's total debt was 123.24 M EUR, a -5.59% change from the 130.53 M EUR total debt recorded in the previous year.

The Stratec Se Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
69.53 M EUR
Jan 1, 2019
93.26 M EUR
Jan 1, 2020
109.58 M EUR
Jan 1, 2021
85.30 M EUR
Jan 1, 2022
87.15 M EUR
Jan 1, 2023
142.06 M EUR
Jan 1, 2024
130.53 M EUR
Jan 1, 2025
123.24 M EUR
The Stratec Se Debt history
YEARDebtYoY
123.24 MEUR-5.59%
130.53 MEUR-8.12%
142.06 MEUR+63.01%
87.15 MEUR+2.17%
85.30 MEUR-22.16%
109.58 MEUR+17.50%
93.26 MEUR+34.12%
69.53 MEUR+11.25%
62.51 MEUR-12.60%
71.51 MEUR+1,300.57%
5.11 MEUR-43.99%
9.12 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Debt Details

Understanding Stratec Se's Debt Structure

Stratec Se's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Stratec Se's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Stratec Se’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Stratec Se’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Stratec Se stock

Debt of Stratec Se is 123.24 M EUR in 2025.

Debt of Stratec Se changed from 130.53 M EUR to 123.24 M EUR, representing a -5.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Stratec Se since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Stratec Se historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Stratec Se

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Stratec Se